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The EU-sponsored LEISHDRUG consortium uses a
highly interdisciplinary approach to reveal Leishmania
signaling molecules associated with virulence of the
pathogenic amastigote stage. LEISHDRUG coordinates
the efforts of 13 partners across eight nations, including
four institutes of the Institut Pasteur international net-
work, with the major aim to exploit the Leishmania
kinome for anti-parasitic drug development.
The consortium is based on three clusters with each
two interactive scientific work packages that together
follow the major stages of the drug development pro-
cess, including identification of hit compounds and
target kinases, hit-to-lead validation and lead charac-
terization. We use innovative drug screening concepts
not applied previously on parasitic systems, including
visual high-content screening to discover compounds
capable to kill intracellular Leishmania amastigotes
without deteriorating the host cell. This phenotype-
based strategy relies on fluorescent parasites and
macrophages as read-outs and will allow simultaneous
assessment of anti-leishmanial activity and host cell
toxicity under physiological conditions. We apply a
target-based strategy utilizing recombinant Leishmania
protein kinases for inhibitor identification and struc-
ture-guided drug design. The identification of appro-
priate target kinases, with only limited homology to
their mammalian counterparts relies on in silico analy-
sis by applying novel bioinformatic tools developed by
consortium members, and in vitro assays based on
their phospho-transferase activity towards recombinant
Leishmania phospho-proteins.
The major objectives of our consortium are (i) to
screen small molecule and peptide libraries for hit com-
pounds with leishmanicidal activity using phenotype- and
target-based strategies, (ii) to identify anti-parasitic lead
compounds and assess their pharmacokinetic profiles
using cell-culture and experimental infection models for
leishmaniasis, and (iii) to initiate lead optimization by
structure-based drug design.
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